Meseko Clement A, Shittu Ismaila, Asala Olayinka O, Adedeji Adeyinka J, Laleye Tinuke A, Agusi Ebere R, Gado Dorcas A, Olawuyi Kayode A, Mkpuma Nicodemus, Chinonyerem Chinyere, Inuwa Bitrus, Chima Nneka, Akintola Ruth, Nyango Patrick, Luka Hellen, Bakam Judith, Atai Rebecca, Kabantiyok Dennis, Samson Mark, Daniel ThankGod, Oyetunde Joshua, Owolodun Olajide A, Lazarus David D, Obishakin Emmanuel T, Luka Pam D, Audu Benshak J, Makama Sunday, Ularamu Hussaini G, Wungak Yiltawe S, Ahmed James S, Ocholi Reuben A, Muhammad Maryam
Department of Infectious and Transboundary Animal Diseases (ITADs), National Veterinary Research Institute, Vom Plateau State.
Onderstepoort J Vet Res. 2024 Sep 4;91(2):e1-e6. doi: 10.4102/ojvr.v91i2.2156.
The COVID-19 pandemic has caused the death of 7.1 million people worldwide as of 7 July 2024. In Nigeria, the first confirmed case was reported on 27 February 2020, subsequently followed by a nationwide spread of SARS-CoV-2 with morbidity and mortality reaching 267 173 and 3155, respectively, as of 7 July 2024. At the beginning of the pandemic, only a few public health laboratories in Nigeria had the capacity for SARS-CoV-2 molecular diagnosis. The National Veterinary Research Institute (NVRI), already experienced in influenza diagnosis, responded to the public health challenge for the diagnosis of COVID-19 samples from humans. The feat was possible through the collective utilisation of NVRI human and material resources, including biosafety facilities, equipment, reagents and consumables donated by international partners and collaborators. Within 6 months of the reported COVID-19 outbreak in Nigeria, over 33 000 samples were processed in NVRI facilities covering five states. Thereafter, many field and laboratory projects were jointly implemented between NVRI and collaborating sectors including the Nigerian Centre for Disease Control (NCDC) and the National Institute for Medical Research (NIMR), which brought together professionals in the health, veterinary, education and socio-sciences. In addition, One Health grants were secured to enhance surveillance for coronavirus and other zoonoses and build capacity in genomics. Bio-surveillance for coronaviruses and other emerging zoonotic pathogens at the human-animal interface was activated and continued with sample collection and analysis in the laboratory for coronaviruses, Lassa fever virus and Mpox. One Health approach has shown that inter-sectoral and multinational collaboration for diagnosis, research and development in animals, and the environment to better understand pathogen spillover events at the human-animal interface is an important global health priority and pandemic preparedness.
截至2024年7月7日，新冠疫情已导致全球710万人死亡。在尼日利亚，2020年2月27日报告了首例确诊病例，随后SARS-CoV-2在全国范围内传播，截至2024年7月7日，发病率和死亡率分别达到267173例和3155例。在疫情初期，尼日利亚只有少数公共卫生实验室具备SARS-CoV-2分子诊断能力。国家兽医研究所（NVRI）在流感诊断方面已有经验，应对了来自人类的新冠病毒样本诊断的公共卫生挑战。通过集体利用NVRI的人力和物力资源，包括国际合作伙伴和协作者捐赠的生物安全设施、设备、试剂和耗材，这一壮举得以实现。在尼日利亚报告新冠疫情爆发后的6个月内，NVRI设施处理了覆盖五个州的超过33000份样本。此后，NVRI与包括尼日利亚疾病控制中心（NCDC）和国家医学研究所（NIMR）在内的合作部门联合实施了许多实地和实验室项目，这些项目汇聚了卫生、兽医、教育和社会科学领域的专业人员。此外，还获得了“同一健康”赠款，以加强对冠状病毒和其他人畜共患病的监测，并建设基因组学能力。启动了对人兽界面冠状病毒和其他新兴人畜共患病原体的生物监测，并继续在实验室对冠状病毒、拉沙热病毒和猴痘进行样本采集和分析。“同一健康”方法表明，跨部门和跨国在动物和环境方面进行诊断、研发合作，以更好地了解人兽界面的病原体溢出事件，是一项重要的全球卫生优先事项和大流行防范措施。
